Table 1. N indicates the number of subjects per experimental group. Abbreviations: KO; knockout, Il-6; interleukin-6, TNFα; tumour necrosis factor-alpha, Ccl6; chemokine (C-C motif) ligand 6, Ccl7; chemokine (C-C motif) ligand 7, Ccl9; chemokine (C-C motif) ligand 9, Foxp3; forkhead box P3, Bcl11A; BAF chromatin remodelling complex subunit BCL11A, RunX1; RUNX family transcription factor 1, Cbfβ; core binding factor β, GFI1; growth factor independent 1 transcription repressor, LSD1; lysine demethylase 1A, H3K36me2; histone 3 lysine 36 dimethylation, NFκB; nuclear factor kappa B subunit 1, ERK; extracellular signal-regulated kinase, LPS; lipopolysaccharide, CCL2; C-C motif chemokine ligand 2, H3K36me3; histone 3 lysine 36 trimethylation, RunX2; RUNX family transcription factor 2, Myc; myelocytomatosis oncogene, HIV-1; immunodeficiency virus type 1, H4K20me1; histone 4 lysine 20 monomethylation, L3MBTL1; L3MBTL histone methyl-lysine binding protein 1, IFNγ; interferon gamma, CSF1; colony-stimulating factor 1, T1DM; type 1 diabetes, T2DM; type 2 diabetes, S100A12; S100 calcium binding protein A12, HTLV-1; human T-cell lymphotropic virus type 1/ human T-cell leukaemia type 1, H3K4me3; histone 3 lysine 4 trimethylation, iTreg; inducible regulatory T cells, H3K4me; histone 3 lysine 4 methylation, 15-LOX-1; 15-Lipoxygenase-1, STAT3; signal transducer and activator of transcription 3, Cxcl9; C-X-C motif chemokine ligand 9, Cxcl10; C-X-C motif chemokine ligand 10, Cxcl11; C-X-C motif chemokine ligand 11, Tap1; transporter 1, ATP binding cassette subfamily B member, TLR4; Toll-like receptor 4, H4K20me3; histone 4 lysine 20 trimethylation.